99 related articles for article (PubMed ID: 6575208)
1. Prognostic significance of leukocyte-dependent antibody activity in melanoma patients.
Hersey P; Edwards A; Murray E; McCarthy WH; Milton GW
J Natl Cancer Inst; 1983 Jul; 71(1):45-53. PubMed ID: 6575208
[TBL] [Abstract][Full Text] [Related]
2. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen.
Jones PC; Sze LL; Liu PY; Morton DL; Irie RF
J Natl Cancer Inst; 1981 Feb; 66(2):249-54. PubMed ID: 6935475
[TBL] [Abstract][Full Text] [Related]
4. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous melanomas that defy conventional prognostic indicators.
McCarthy WH; Shaw HM; McCarthy SW; Rivers JK; Thompson JF
Semin Oncol; 1996 Dec; 23(6):709-13. PubMed ID: 8970591
[TBL] [Abstract][Full Text] [Related]
6. The cell-mediated immunity in patients with malignant melanoma.
Fixa B; Komárková O; Kraus Z; Simková H
Neoplasma; 1978; 25(3):353-7. PubMed ID: 683378
[TBL] [Abstract][Full Text] [Related]
7. Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.
Litvak DA; Gupta RK; Yee R; Wanek LA; Ye W; Morton DL
J Am Coll Surg; 2004 Jan; 198(1):27-35. PubMed ID: 14698308
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
[TBL] [Abstract][Full Text] [Related]
9. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
10. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Hart GA; Kroon BB
Ann Surg Oncol; 2004 May; 11(5):491-9. PubMed ID: 15078633
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma.
Henrique R; Azevedo R; Bento MJ; Domingues JC; Silva C; Jerónimo C
J Am Acad Dermatol; 2000 Dec; 43(6):991-1000. PubMed ID: 11100014
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
16. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
17. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
18. Prognostic variables for patients with stage III malignant melanoma.
Messaris GE; Konstadoulakis MM; Ricaniadis N; Leandros E; Androulakis G; Karakousis PC
Eur J Surg; 2000 Mar; 166(3):233-9. PubMed ID: 10755339
[TBL] [Abstract][Full Text] [Related]
19. Blocking factors against melanoma leucocyte-dependent antibody: relationship to disease activity in melanoma patients.
Hersey P; Murray E; Ruygrok S; Edwards A; Milton GW
Aust N Z J Surg; 1978 Feb; 48(1):26-32. PubMed ID: 276346
[TBL] [Abstract][Full Text] [Related]
20. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
